# REATA PHARMACEUTICALS INC (RETA)

> Institutional ownership reported to the SEC as of Q3 2023, from Form 13F filings. Source: https://holderbook.com/stocks/RETA/

- Reporting holders: 4
- Reported value: $70.2M
- Held through calls: 23.5%
- Held through puts: 72.3%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [Maven Securities LTD](https://holderbook.com/funds/1633046-maven-securities-ltd/) | $66.4M | 0 | 0.8% | 1 |
| [DekaBank Deutsche Girozentrale](https://holderbook.com/funds/1456228-dekabank-deutsche-girozentrale/) | $2.9M | 17,000 | 0.0% | 16 |
| [SIMPLEX TRADING, LLC](https://holderbook.com/funds/1488542-simplex-trading-llc/) | $807.0K | 0 | 0.0% | 20 |
| [IFP Advisors, Inc](https://holderbook.com/funds/1641866-ifp-advisors-inc/) | $51.7K | 300 | 0.0% | 13 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q3 2023 | 4 | $70.2M |
| Q2 2023 | 220 | $3.4B |
| Q1 2023 | 210 | $2.9B |
| Q4 2022 | 171 | $1.2B |
| Q3 2022 | 158 | $780.5M |
| Q2 2022 | 143 | $864.3M |
| Q1 2022 | 150 | $978.0M |
| Q4 2021 | 152 | $744.9M |
| Q3 2021 | 190 | $2.8B |
| Q2 2021 | 202 | $3.8B |
| Q1 2021 | 204 | $2.6B |
| Q4 2020 | 203 | $3.1B |